Vyvanse added to the Essential Formulary with Prior Authorization and Step Therapy
May 26, 2022
Effective June 1, 2022, Vyvanse capsules and chewable tablets will be added to the Essential Formulary as tier 4 medications. Vyvanse will require prior authorization with step therapy before a member will receive approval for the drug. The existing quantity limit of 1 capsule/tablet per day will remain in place.
No additional authorization is needed if a prior authorization was approved for a member in 2022, while Vyvanse required a formulary exception.
View the new coverage policy (PDF).